Blood test after transplant may flag hidden virus risk

NCT ID NCT06814301

Not yet recruiting Knowledge-focused Sponsor: Maimónides Biomedical Research Institute of Córdoba Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 123 stem cell transplant patients to see if measuring their immune response to CMV after stopping a preventive drug (letermovir) can predict late infections. Participants will have regular blood tests up to 200 days after transplant. The goal is to learn whether a weak immune response signals higher risk, which could help tailor future prevention.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors personalize how long CMV prevention is needed after a stem cell transplant, reducing late infections.
What could go wrong: This is an observational study, not a treatment trial. It may not prove that immune monitoring directly improves outcomes, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS CELL MEDIATED IMMUNITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYTOMEGALOVIRUS CELL MEDIATED IMMUNITY STEM CELL TRANSPLANTATION, HEMATOPOIETIC

Contacts and locations

Locations

Hospital Universitario Reina Sofía

Córdoba, Córdoba, 14004, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.